insights_auto
Why is BCRX up 3.40%?
Dive Deeperchevron_right
BCRX:NASDAQ
BioCryst Pharmaceuticals Inc
$8.06
arrow_upward
+3.40%(+0.27) 1D
Oct 19, 3:32:47 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BCRX...
Open
$7.77
High
$8.08
Low
$7.77
Mkt. cap
2.06B
Avg. vol.
5.39M
Volume
6.36M
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
Open
$7.77
High
$8.08
Low
$7.77
Mkt. cap
2.06B
Avg. vol.
5.39M
Volume
6.36M
52-wk high
$11.22
52-wk low
$6.23
EPS
-$1.50
Beta
0.55
Shares outstanding
255.54M
No. of employees
435
News stories
From web sources and news partners
The Motley Fool
·
7 minutes ago
3 Unstoppable Dow Stocks to Buy Before October Ends
TradingView
·
1 hour ago
Broader S&P 500 set to outpace Mag 7 in earnings growth for first time since 2022
The Lufkin Daily News
·
1 hour ago
Nasdaq climbs as chip and AI-linked stocks bounce back
Yahoo Finance
·
10 hours ago
Is Invesco S&P 500 Equal Weight Consumer Staples ETF (RSPS) a Strong ETF Right Now?
Profile
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema and other rare diseases. BioCryst's antiviral drug peramivir was approved by the FDA in December 2014 and berotralstat was approved in December 2020. Wikipedia
About BioCryst Pharmaceuticals Inc
CEOJon P. Stonehouse
Employees435
Founded1986
HeadquartersDurham, North Carolina, United States
SectorBiotechnology
Websitebiocryst.com